In June 2025, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a new indication for Sarclisa, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma. (ema.europa.eu)
In November 2024, the CHMP recommended a new indication for Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. (ema.europa.eu)
In April 2025, the EMA granted conditional marketing authorization for Lynozyfic (linvoseltamab) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior therapies. (ema.europa.eu)
In January 2024, the EMA recommended the non-renewal of the marketing authorization for Blenrep, a multiple myeloma medicine, due to its failure to demonstrate effectiveness compared to pomalidomide plus low-dose dexamethasone. (ema.europa.eu)
In December 2023, the EMA adopted a positive opinion for Pomalidomide Viatris, a generic version of pomalidomide, indicating the growing acceptance and availability of generic alternatives in the European market. (ema.europa.eu)
These developments highlight the dynamic nature of the multiple myeloma treatment landscape and the importance of staying abreast of regulatory changes and market trends.
